TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. (April 2017)

• Record Type: Journal Article
• Authors: Wang, Xiaoyan; Lopez-Beltran, Antonio; Osunkoya, Adeboye O; Wang, Mingsheng; Zhang, Shaobo; Davidson, Darrell D; Emerson, Robert E; Williamson, Sean R; Tan, Puay-Hoon; Kaimakliotis, Hristos Z; Baldridge, Lee Ann; MacLennan, Gregory T; Montironi, Rodolfo; Cheng, Liang
• Is Part Of: Future oncology. Volume 13:Number 8(2017)
• Page Start: 705
• Page End: 714
• Publication Date: 2017-04
• Subjects: biomarkers -- bladder -- GATA3 -- sarcomatoid urothelial carcinoma -- TERT promoter mutation -- upper urinary tract -- ureter; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0414
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma.Methods & results: TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery.Conclusion: Sarcomatoid carcinoma of the upper urinary tract is an aggressive tumor and the presence of TERT mutation may portend poor prognosis.